Core Insights - Polaryx Therapeutics is advancing its investigational therapy PLX-200 for Krabbe disease, presenting new data at the 22nd Annual WORLDSymposium™ [1][2] - The SOTERIA trial, a Phase 2 study, aims to assess the safety and efficacy of PLX-200 across multiple lysosomal storage disorders (LSDs) [2][5] Company Overview - Polaryx Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare orphan lysosomal storage disorders, founded in 2014 [7] - The company aims to deliver patient-friendly treatments that address the underlying pathophysiology of these diseases [7] Product Information - PLX-200 is an orally available compound based on gemfibrozil, which has been used in adults but never approved for pediatric indications [4] - The drug's ability to cross the blood-brain barrier positions it as a potential treatment for multiple rare LSDs [4] Clinical Trial Details - The SOTERIA trial will include patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease, representing about 25% of the LSD population [5] - The trial is designed to be flexible and resource-efficient, with plans to initiate in the first half of 2026 [5][6] Presentation Information - Shrijay Vijayan, Chief Scientific and Business Development Officer, will present preclinical findings on PLX-200 in a mouse model of Krabbe disease on February 6, 2026 [3]